Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Age 13 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key points about the study:
- The treatment involves a unique combination of drugs that target the cancer cells in different ways, potentially leading to better results than traditional therapies.
- Patients will receive the treatment in a controlled environment, allowing researchers to closely monitor its effects and adjust as needed.
- This study is designed to evaluate not only the effectiveness of the treatment but also its safety and how well patients tolerate it.
- Participants will be closely followed for a significant period, providing valuable data on long-term outcomes and any side effects.
- The study aims to include a diverse group of patients to ensure the findings are applicable to a wide range of individuals affected by this condition.
Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
